Ten-Year Experience With Stentless Aortic Valves: Full-Root Versus Subcoronary Implantation
|
|
- Bridget Barrett
- 5 years ago
- Views:
Transcription
1 Ten-Year Experience With Stentless Aortic Valves: Full-Root Versus Subcoronary Implantation Juergen A. C. Ennker, MD, Alexander A. Albert, MD, Ulrich P. Rosendahl, MD, Ina C. Ennker, MD, Fatmir Dalladaku, MD, and Ines Florath, PhD Department of Cardiothoracic Surgery, Heart Institute Lahr/Baden, Lahr, and Institute of Cardiovascular Medicine of the University Witten-Herdecke, Witten, Germany Background. We compared the midterm outcome after aortic valve replacement with the Freestyle stentless bioprosthesis for the full-root or subcoronary implantation technique, while adjusting for patient and disease characteristics by a propensity score. Methods. Between 1996 and 2005, 1,014 patients underwent aortic valve replacement with the stentless Medtronic Freestyle bioprosthesis, 168 using full-root technique. Based on a saturated propensity score, 148 matched pairs were created. Mean age of the 296 patients was 73 3 years. Mean follow-up time was months (maximum, 116 months). Results. Operative mortality was 4.7% and 2.7% (p 0.36) in the full-root and subcoronary groups, respectively. Freedom from reoperation, prosthetic valve endocarditis, major bleeding, and thromboembolism after 9 years was 98% 1% and 90% 7% (p 0.38), 95% 3% and 92% 7% (p 0.76), 72% 21% and 98% 2% (p 0.12), and 75% 8% and 84% 7% (p 0.28), for full-root and subcoronary groups, respectively. Survival rates after 9 years were 34% 24% and 33% 11% (p 0.46), for the full-root and subcoronary groups, respectively. Patients in the full-root group received larger valve sizes (p 0.03), and the mean transprosthetic gradients at discharge were significantly lower for each valve size. Nevertheless, during follow-up, peak gradients decreased to a greater extent in patients presenting high peak gradients (>36 mm Hg) at discharge. Conclusions. As risk-adjusted comparison of both implantation techniques did not reveal any differences regarding operative and midterm outcomes, full-root replacement can be liberally performed in patients with small aortic roots, annuloaortic ectasia, or requiring replacement of ascending aorta. (Ann Thorac Surg 2008;85:445 53) 2008 by The Society of Thoracic Surgeons Biologic heart valve prostheses offer the opportunity of avoiding anticoagulation and, therefore, the risk of thromboembolic and hemorrhagic complications. Current indications recommend a bioprosthesis for aortic valve replacement (AVR) in patients of any age who will not take warfarin or who have major medical contraindications to anticoagulation therapy (class I), in patients older than 65 years without risk factors for thromboembolism (class IIa), and in patients younger than 65 years for lifestyle considerations after detailed discussion of the risks of anticoagulation versus the likelihood of a second valve replacement [1]. The Medtronic Freestyle bioprosthesis is an intact porcine root with ligated coronary arteries. Similar to the use of different implant techniques with human tissue valves, the Freestyle aortic root bioprosthesis can be implanted by several surgical techniques: complete or modified subcoronary, root inclusion, and full root. Using human tissue valves, aortic root replacement was associated with a lower incidence of early reoperation, greater Accepted for publication Oct 2, Presented at the Forty-third Annual Meeting of The Society of Thoracic Surgeons, San Diego, CA, Jan 29 31, Address correspondence to Dr Florath, Heart Institute Lahr/Baden, Hohbergweg 2, Lahr, D-77933, Germany; ines.florath@heartlahr.com. effective orifice area, and less prominent aortic regurgitation on Doppler echocardiography [2, 3] in comparison with the subcoronary technique. However, contradictory results exist neglecting the superiority of the root replacement technique with regard to aortic regurgitation [4, 5]. The only comparison of different implantation techniques for porcine stentless bioprostheses reported higher operative mortality and better hemodynamics, functional class, and freedom from regurgitation with full-root in comparison to the subcoronary implantation technique [6]. Which surgical technique to use subcoronary implantation or aortic root replacement is still under debate. The purpose of the present study was to compare early and late outcomes after AVR with stentless valves for the subcoronary versus full-root implantation technique. As the clinical characteristics differ among patients receiving stentless bioprostheses in different implantation techniques, we adjusted for these confounding factors by a propensity score based matching analysis [7]. Drs J. Ennker and Florath disclose that they have a financial relationship with Medtronic Inc by The Society of Thoracic Surgeons /08/$34.00 Published by Elsevier Inc doi: /j.athoracsur
2 446 ENNKER ET AL Ann Thorac Surg FULL-ROOT VERSUS SUBCORONARY IMPLANTATION 2008;85: Patients and Methods Between April 1996 and November 2005, 1,014 patients underwent AVR with the stentless biological Medtronic Freestyle prosthesis (Medtronic Inc, Minneapolis, MN), 168 of them in full-root technique. The surgical technique has been previously described [8]. The prosthesis type, surgical technique, and size selection was according to the surgeon s preference. The surgical strategy for the subcoronary versus full-root technique changed over the years for all surgeons. At the beginning the subcoronary technique was nearly always used. With increased experience we tended to use stentless valve implantation with full-root replacement liberally in smaller annulus or in annuloaortic ectasia. In all patients with dilatation of the ascending aorta greater than 4 cm, we performed the full-root technique in combination with ascending aorta replacement using a vascular Hemashield prosthesis. The full-root technique was not clustered to a limited number of experienced surgeons implanting stentless valves. Preoperative and intraoperative data were collected on all patients as a part of a national quality assessment trial of cardiothoracic surgery (Quadra; Quality Assurance Data Review Analysis) using standardized protocols of the German Society of Thoracic and Cardiovascular Surgery [9]. Transthoracic echocardiographic control before hospital discharge (within 10 days after AVR) under rest was performed in all patients by experienced cardiolo- Table 1. Preoperative Patient Characteristics a All Patients Matched Patients Characteristic Subcoronary Full Root p Value Subcoronary Full Root p Value N Female 402 (47.6) 104 (61.5) (64.2) 95 (64.2) Age (y) Body height (cm) Body surface area (m 2 ) Body mass index (kg/m 2 ) Left ventricular ejection fraction (%) History of CHF 151 (17.9) 34 (20.1) (23.0) 33 (22.3) 0.89 History of myocardial infarction 92 (10.9) 12 (7.1) (6.1) 11 (7.4) 0.64 Diabetes mellitus 217 (25.7) 38 (22.5) (25.0) 37 (25.0) Atrial fibrillation 101 (12.0) 18 (10.7) (13.5) 19 (12.8) 0.86 Hypertension 598 (70.8) 128 (75.7) (67.6) 114 (77.0) 0.07 Hyperlipidemia 390 (46.2) 81 (47.9) (48.6) 73 (49.3) 0.91 Peripheral occlusive arterial disease 44 (5.2) 11 (6.5) (3.4) 10 (6.8) 0.19 Chronic pulmonary disease 227 (26.9) 37 (21.9) (20.9) 34 (23.0) 0.67 History of renal disease 160 (18.9) 29 (17.2) (14.2) 26 (17.6) 0.43 Neurologic disorders 60 (7.1) 16 (9.5) (7.4) 14 (9.5) 0.53 Internal carotid artery stenosis 73 (8.6) 14 (8.3) (6.8) 13 (8.8) 0.52 Any acute infection 25 (3.0) 5 (3.0) 5 (3.4) 5 (3.4) Aortic valve endocarditis 16 (1.9) 1 (0.6) (2.0) 1 (0.7) 0.62 NYHA class I 50 (5.9) 9 (5.3) 8 (5.4) 7 (4.7) II 398 (47.1) 71 (42) 65 (43.9) 61 (41.2) III 342 (40.5) 75 (44.4) 69 (46.6) 68 (45.9) IV 55 (6.5) 14 (8.3) 6 (4.1) 12 (8.1) Replacement of ascending aorta 22 (2.6) 37 (21.9) (11.5) 17 (11.5) Concomitant MVR 22 (2.6) 3 (1.8) (4.7) 2 (1.4) 0.17 Concomitant CABG 330 (39.1) 52 ( (28.4) 47 (31.8) 0.53 Previous open heart surgery 28 (3.3) 8 (4.7) (5.4) 7 (4.7) 0.79 Emergency procedure 17 (2.0) 4 (2.4) (1.4) 4 (2.7) 0.41 Aortic lesion Stenosis 459 (54.3) 95 (56.2) (52.0) 87 (58.8) 0.24 Regurgitation 74 (8.8) 22 (13) (11.5) 14 (9.5) 0.57 Mixed 310 (36.7) 50 (29.6) (36.5) 45 (30.4) 0.27 a Values are number (%) or mean standard deviation. CABG coronary artery bypass grafting; CHF congestive heart failure; MVR mitral valve replacement; NYHA New York Heart Association.
3 Ann Thorac Surg ENNKER ET AL 2008;85: FULL-ROOT VERSUS SUBCORONARY IMPLANTATION 447 Fig 1. Survival curves by implant technique in comparison with the general German population. gists. Mean transvalvular pressure gradients were calculated by continuous-wave Doppler using the modified Bernoulli equation. The retrospective study was approved by the ethics committee of the General Medical Council of the state of Baden-Württemberg, Germany. The approval incorporates written informed consent regarding participation in the study and inspection of the echocardiographic data obtained by their family cardiologist. Follow-Up Follow-up information was obtained between January and April 2006 by mailed questionnaires and completed by telephone interviews. Follow-up information concerning survival and adverse valve-related events was 99% and 93% complete, respectively. To complete the adverse events of deceased patients, the information from follow-up conducted in 2000, 2001, and 2003 was used. The questionnaire consists of a quality-of-life assessing questionnaire, the Nottingham Health Profile, and general questions concerning further stay in hospital care since valve replacement, New York Heart Association status, postoperative complications, and current symptoms such as arrhythmias, dizziness, and sensory disturbances in limbs and arms. The Nottingham Health Profile contains 38 subjective statements divided into six sections: energy, pain, emotional reaction, sleep, social isolation, and physical mobility. The number of statements in each section varies from three in the energy section to nine in the emotional reaction section. Scale scores range from 0 to 100 with a lower score indicating a better perceived quality of life [10]. Sixty-eight percent of all survivors (n 525) responded to the mailed questionnaire, assessing quality of life. Reasons for not responding were need of care (6%, n 16), too strenuous (14%, n 38), illness (9%, n 23), disagreement (5%, n 11), stay abroad (1%, n 3), and without reason (willingly answered on the phone; however, did not return the questionnaire, 59%, n 156). Statistical Analysis Statistical analysis was performed using the software package SPSS (SPSS Inc, Chicago, IL). All continuous data were expressed as mean values ( one standard deviation or standard error of the mean) and compared by the Mann-Whitney U test. Dichotomous variables were evaluated by the univariable 2 test and Fisher s exact test. Survival and freedom from valve-related adverse events were estimated by the Kaplan Meier method and compared by the log-rank test. To account for imbalances in the distribution of risk factors between patients receiving the Freestyle bioprosthesis in the subcoronary (SC group) or full-root technique (FR group), a saturated propensity score was calculated by logistic regression, including variables presented in Table 1 irrespective of their significance level [11]. Patients of the SC group were then matched one-toone with the patients of the FR group by the nearest propensity score (maximum difference, 0.05; 90% were 0.01), which was the probability to receive the Freestyle bioprosthesis using the full-root technique, and by the time of the surgery to avoid different follow-up times between the groups. Table 1 shows the preoperative and operative characteristics for all and for matched patients. Results The operative mortality (within 30 days) was 2.7% (n 4) and 4.7% (n 7), respectively, for the subcoronary and full-root implantation technique with no significant difference between the two groups (p 0.36). Mean cardiopulmonary bypass time was significantly longer for patients who received the stentless valve in the full-root technique (SC, minutes; FR, minutes; p 0.02), whereas the cross-clamp times did not differ (SC, minutes; FR, minutes; p 0.34). Ventilation time and stay in intensive care unit were days and days, respectively, for the SC group and days and days, respectively, for the FR group (p 0.19; p 0.16, respectively). Fig 2. Scores (mean standard error of the mean) for the different sections of the Nottingham Health Profile (NHP) questionnaire for patients who received stentless valves in subcoronary (open bar) or in full root technique (solid bar) in comparison to the scores obtained for men and women of the general German population older than 71 years (left and right hatched bar, respectively).
4 448 ENNKER ET AL Ann Thorac Surg FULL-ROOT VERSUS SUBCORONARY IMPLANTATION 2008;85: Coronary complications occurred in 2 patients receiving the full-root technique with a rate of 1.4%, which was not significantly different from the subcoronary technique (p 0.5). Operative bleeding was observed in 8 patients of the SC group (5.4%) and in 6 patients of the FR group (4.1%; p 0.6). Mean follow-up time was years (maximum, 9.4 years) and years (maximum, 9.7 years), respectively, for the SC and FR groups (p 0.83). Overall survival was 71% 33% and 78% 29% after 5 years and 33% 20% and 34% 24% after 9 years, respectively, for the SC and FR groups (p 0.46) and was compared with men and women of the general German population with the mean age of the study population [12] (Fig 1). Causes of death after 5 years were of a cardiac nature in 4 patients, cancer in 3 patients, stroke in 2 patients, pulmonary embolism in 1 patient with multiple morbidity such as diabetes mellitus and generalized atherosclerotic disease, re-replacement of the bioprosthesis because of prosthetic valve endocarditis in 1 patient, and unknown in 2 patients. Health-related quality of life was obtained in 63% and 68% of surviving patients, respectively, in the SC and in the FR group. Quality of life was assessed at the time of follow-up in 2006 with no difference in time course between the two groups (p 0.21). The means of the scores of the different Nottingham Health Profile sections are shown by implantation technique in Figure 2. No Fig 3. Transvalvular mean pressure gradients (mean standard deviation) for each valve size by implant technique (A; subcoronary, white bars; full root, black bars); transvalvular peak gradients at different follow-up times in comparison with the peak gradients at discharge for the subcoronary (B) and full-root techniques (C). The lines between the gradients at follow-up time and at discharge show the amount of increase (solid line) or decrease (dotted line) in the peak gradient by follow-up time.
5 Ann Thorac Surg ENNKER ET AL 2008;85: FULL-ROOT VERSUS SUBCORONARY IMPLANTATION 449 significant difference was observed for quality of life after AVR with stentless bioprostheses between the different implantation techniques in the different sections. The mean scores for our study population with a mean age of 73 years were similar to the scores of men and women of the general German population older than 71 years obtained from Hinz and colleagues [13]. Hemodynamics Valve sizes 19, 21, 23, 25, and 27 mm were implanted: 2%, 28%, 30%, 29%, and 11% in the SC and 14%, 44%, 26%, 14%, and 2% in the FR groups, respectively. In Figure 3A, the mean transvalvular pressure gradients at discharge are presented by valve size and implantation technique, and in Figures 3B and 3C, the peak transvalvular pressure gradients at different follow-up times are compared with the peak gradients at discharge for the subcoronary and full-root implantation technique, respectively. The gradients in most patients decreased during follow-up time. According to the ACC/AHA Practice Guidelines for the Management of Patients With Valvular Heart Disease, the degree of aortic stenosis is defined by echocardiographic data as mild (jet velocity 3 m/s, mean gradient 25 mm Hg), moderate (jet velocity 3 to 4 m/s, mean gradient 25 to 40 mm Hg), and severe (jet velocity 4 m/s, mean gradient 40 mm Hg) [1]. Especially in patients presenting a moderate aortic stenosis at discharge, by this definition the gradients decreased to a greater extent on average by 20 mm Hg versus 4 mm Hg. At discharge, 36% and 5% of the patients were classified as having moderate aortic stenosis, respectively, in the SC and in the FR groups, and at follow-up, 9% in the SC group and no patient in the FR group. At follow-up, 29% of the patients receiving a size 19 or 21 stentless valve in subcoronary technique exhibited a moderate aortic stenosis. The average peak gradients at discharge and at follow-up time were mm Hg and mm Hg, respectively, for the SC group (n 44) and 18 6mmHg and 13 5 mm Hg, respectively, for the FR group (n 43), for patients in whom both measurements were obtained. At discharge, 93.4% in the SC and 99.2% in the FR groups (p 0.02) had no aortic regurgitation. At follow-up time, 93% of the patients had no aortic regurgitation in either group. Valve-Related Morbidity Actuarial freedom from aortic valve reoperation was 97% 15% and 98% 14% after 5 years and 90% 25% Fig 4. Freedom from reoperation (A), freedom from prosthetic valve endocarditis (PVE; B), freedom from major bleeding events (C), and freedom from neurologic events (D). Numbers below the graphs represent patients at risk.
6 450 ENNKER ET AL Ann Thorac Surg FULL-ROOT VERSUS SUBCORONARY IMPLANTATION 2008;85: Table 2. Indications for Reoperation After Atrial Valve Replacement With Stentless Valves by Implant Technique Subcoronary Full Root Indications for Reoperation N Implant Duration Valve Type of Re-Replacement N Implant Duration Valve Type of Re-Replacement Prosthetic valve endocarditis 1 80 months Hancock II 2 6 and 12 months Tissuemed aortic root, Freestyle FR Structural valve deterioration (stenosis) 1 24 months SJM Nonstructural valve dysfunction Paravalvular leak 1 1 day SJM Hemodynamics 1 11 days Carbomedics FR full root; SJM St. Jude Medical. and 98% 14% after 9 years for the SC and the FR groups, respectively (Fig 4A). In the observed study population, 6 patients had to be reoperated on within 747 patient-years, with a linearized rate of late reoperations of 0.54%/patient-year. The indications for reoperations and the implant duration are shown in Table 2. Freedom from prosthetic valve endocarditis was 99% 8% and 98% 14% after 5 years and 92% 26% and 95% 18% after 9 years for the SC and the FR groups, respectively (Fig 4B). The linearized rate of late prosthetic valve endocarditis was 0.67%/patient-year for the entire matched population. In the SC group, prosthetic valve endocarditis occurred in 2 patients after 2 and 80 months. In one of them, the diseased valve had been recently replaced. The other patient died after discharge in another hospital as a result of prosthetic valve endocarditis. In the FR group, prosthetic valve endocarditis occurred in 3 patients, in 2 of whom the diseased valve was replaced. Both patients died. One patient was treated conservatively and survived 4 years. Freedom from major bleeding was 98% 12% and 96% 18% after 5 years and 98% 12% and 72% 36% after 9 years for the SC and the FR groups, respectively (Fig 4C), and freedom from neurologic events was 90% 20% and 84% 27% after 5 years and 84% 27% and 75% 28% after 9 years for the SC and the FR groups, respectively (Fig 4D). The linearized rates were 0.69%/ patient-year and 2.5%/patient-year for bleeding and neurologic events, respectively. Anticoagulation therapy was required in 19% of the patients in the SC group and 23% in the FR group because of generalized atherosclerotic disease and chronic atrial fibrillation occurring postoperatively or during the follow-up time. Comment In observational, nonrandomized studies characteristics differ among patients belonging to the different groups of comparison as a result of clinically motivated patient selection or chance. These different patient characteristics may affect different outcomes between groups of comparison besides the variable of comparison, ie, the treatment or, in the present study, the implantation technique [7]. To balance or adjust these effects, a propensity score was proposed by Rosenbaum and Rubin [11]. After adjustment for different patient characteristics by such a propensity score based analysis, no significantly increased operative mortality was observed for the fullroot implantation technique and also no difference was found for midterm survival, midterm valve-related morbidity, and quality of life between different implantation techniques either. Survival and quality of life after AVR with stentless bioprostheses were similar to the age- and gender-matched general German population. Table 3. Linearized Rates of Late Adverse Events (%/Patient-Year) Valve N Age (y) Follow-Up (y) PVE Reoperation Bleeding TE Freestyle [present] Freestyle [16] NA 2.66 CryoLife-O Brien [18] NA 1.56 Toronto SPV [19] NA 0.52 CE-porcine [17] 1, NA 2.33 Stented biologic a [15] NA SJM [15] NA SJM [14] 2, a Hancock porcine, Carpentier-Edwards porcine, or Carpentier-Edwards bovine pericardial. CE Carpentier-Edwards; NA not available; PVE prosthetic valve endocarditis; SJM St. Jude Medical; SPV St. Jude porcine valve; TE thromboembolic event.
7 Ann Thorac Surg ENNKER ET AL 2008;85: FULL-ROOT VERSUS SUBCORONARY IMPLANTATION 451 In Table 3, the linearized rates of late adverse events observed in this study are presented and compared with previous studies of several different aortic valve prostheses. In comparison to mechanical aortic valve prostheses, the Freestyle valve had only slightly increased rates for prosthetic valve endocarditis and reoperation and, as expected, quite lower bleeding rates (Table 3) [14, 15]. The rates in the present study were quite similar to the results reported for other bioprostheses, stented or stentless (Table 3) [16, 17], whereas the studies conducted with stentless valves such as CryoLife-O Brien [18] and Toronto SPV [19] found lower thromboembolic rates (Table 3). However, the complication rates primarily depend on patient-related factors [20]. Comparing the outcome of different studies is quite difficult because of the different baseline characteristics. For instance, the prevalence of risk factors for stroke such as diabetes mellitus, hypertension, atrial fibrillation, left ventricular hypertrophy, and cardiovascular disease may differ in different studies. The prevalence of diabetes mellitus and atrial fibrillation in our study population was twice as high, and the prevalence of hypertension was much higher (70% versus 46% and 38%) than reported for the populations receiving the Toronto SPV [19]. In patients receiving stentless bioprostheses in fullroot technique, lower transvalvular pressure gradients were measured at discharge and at follow-up time in comparison to the subcoronary technique. Within our small patient group for whom we obtained echocardiographic follow-up data, we observed a marked decrease in gradients, which was greater in the subcoronary than in the full-root technique. This phenomenon of decreasing transvalvular gradients with time may be explained by perivalvular hematoma and edema owing to surgical manipulation, which will resolve 3 to 6 months postoperatively [21]. In addition, early postoperative hemodynamics may be influenced by high circulating catecholamines, with elevations in stroke volume and heart rate and subsequently transvalvular flow [22]. However, persistence of higher velocity ratios for a period of 1 year and less complete left ventricular mass regression in 20% of the population were reported. These patients had mean gradients of 20 mm Hg at discharge, were more often women, and had both lower body surface area and smaller valve sizes [23]. Similar results were obtained from studying velocity ratios (peak velocity through the aortic valve to the peak velocity proximal to the valve) rather than transvalvular velocities, to adjust for variations in systolic performance and cardiac output [22, 24]. The clinical implications of these findings and the optimal surgical management still remain controversial. It has already been postulated that the interaction of aortic root anatomy and surgical experience in subcoronary technique is a major determinant of the performance of the Freestyle valve [22, 25]. Thus, it may be possible that in individual cases suboptimal implantation resulting in distortion of the valve or bulking of valve tissue into the outflow tract may be involved in the evolution of higher gradients. In our study, the transvalvular gradients were even higher than reported previously, which may be partly explained by the more frequent use of the subcoronary technique in patients with small aortic roots than in other series. In this context, it is noteworthy that in our series we observed no moderate or severe aortic regurgitation. Only low or trivial aortic regurgitation was observed in the subcoronary technique, but rarely in the full-root group, a finding that was already made in human tissue valves [2, 4] and in porcine stentless valves [16]. Interestingly, in other series a moderate aortic insufficiency was described in a considerable number of patients after subcoronary implantation, but here the gradients were lower [16]. It may be possible that in these series undersizing was more common, whereas in our series, especially at the beginning of our experience, we tended to oversize the valve in the subcoronary technique. Because with oversizing of the valve the risk for higher transvalvular gradients clearly increases, we now strictly avoid this strategy. However, despite these new strategies and increasing experience with the subcoronary technique, a risk of higher gradients using the subcoronary technique remains, which can be avoided using the full-root technique. According to our results, the full-root technique can be applied without any significant increase in operative mortality or morbidity. Similar findings were made by Kunihara and colleagues [26] when stentless valve replacement in the full-root technique was compared with conventional stented valve implantation. Many surgeons are reluctant to perform the full-root technique routinely owing to the known difficulties of this technique as well as the fear of bleeding and coronary complications, especially in the elderly [6]. Nevertheless, with proper training and development of routines, this technique is safe and reproducible and can also be liberally used in the elderly. We perform the full-root technique in patients with small aortic roots, in cases of annuloaortic ectasia and replacement of ascending aorta, and in cases in which a prosthesis-patient mismatch would be expected. A drawback of the full-root implantation technique is the demanding surgery in the case of re-replacement of the aortic valve as a result of prosthetic valve endocarditis or structural valve deterioration. Excellent midterm freedom from reoperation because of structural valve deterioration was reported with approximately 95% at 10 years [16, 27]. Long-term studies showed similar results with stented bioprostheses, whereas the reoperation rate increased more profoundly after 10 to 15 years, especially for patients younger than 60 years [17, 28]. As the maximum follow-up time in the most recent studies of stentless valves is 10 years, no recommendation concerning full-root replacement with stentless bioprosthesis can be given at the moment for younger patients. The present study is a retrospective observational assessment of outcomes obtained by mailed questionnaires and telephone contacts with the patients and their cardiologists. The response rate to the questionnaire was 68% of all survivors. As a consequence, the quality of life may be overestimated as responders judge their own health and their activity better than the nonresponders
8 452 ENNKER ET AL Ann Thorac Surg FULL-ROOT VERSUS SUBCORONARY IMPLANTATION 2008;85: [29]. Nevertheless, the response rate of the compared study assessing quality of life in the general German population was similar (69%) [13]. Only limited echocardiographic data were available at the follow-up time as the follow-up visits were performed by the local cardiologists, and echocardiographic examinations are indicated only in the case of changes of the clinical status. Eighty-five percent of the responders signed the informed consent for contacting their cardiologist to obtain their echocardiograms. As most of the patients (66%) underwent valve replacement during the last 5 years, in most of them an echocardiographic examination was still not performed. The study was supported by Medtronic Inc, Düsseldorf, Germany. We thank Marcella Schabel for assistance with data collection. References 1. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2006;114:e O Brien MF, Harrocks S, Stafford EG, et al. The homograft aortic valve: a 29-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Dis 2001;10: Kilian E, Oberhoffer M, Gulbins H, Uhlig A, Kreuzer E, Reichardt B. Ten years experience in aortic valve replacement with homografts in 389 cases. J Heart Valve Dis 2004;13: Böhm JO, Botha CA, Hemmer W, et al. Hemodynamic performance following the Ross operation: comparison of two different techniques. J Heart Valve Dis 2004;13: Willems TP, van Herwerden LA, Steyerberg EW, et al. Subcoronary implantation or aortic root replacement for human tissue valves: sufficient data to prefer either technique? Ann Thorac Surg 1995;60(Suppl):S Bach DS, Cartier PC, Kon ND, et al. Impact of implant technique following Freestyle stentless aortic valve replacement. Ann Thorac Surg 2002;74: Blackstone EH. Comparing apples and oranges. J Thorac Cardiovasc Surg 2002;123: Ennker J, Rosendahl U, Ennker IC, et al. Risk in elderly patients after stentless versus stented aortic valve surgery. Asian Cardiovasc Thorac Ann 2003;11: Struck E, De Vivie ER, Hehrlein F, et al. Multicentric quality assurance in cardiac surgery. QUADRA study of the German Society for Thoracic and Cardiovascular Surgery (QUADRA: quality data retrospective analysis). Thorac Cardiovasc Surg 1990;38: Kohlmann T, Bullinger M, Kirchberger-Blumstein I. Die deutsche Version des Nottingham Health Profile (NHP): Übersetzungsmethodik und psychometrische Validierung. Soz-Präventivmed 1997;42: Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70: German Federal Statistical Office (Statistisches Bundesamt der BRD, Abgekürzte Sterbetafel, 1996/98), Wiesbaden, Hinz A, Klaiberg A, Schumacher J, Brahler E. The psychometric quality of the Nottingham Health Profile (NHP) in the general population. Psychother Psychosom Med Psychol 2003;53: Emery RW, Krogh CC, Arom KV, et al. The St. Jude medical cardiac valve prosthesis: a 25-year experience with single valve replacement. Ann Thorac Surg 2005;79: Khan SS, Trento A, DeRobertis M, et al. Twenty-year comparison of tissue and mechanical valve replacement. J Thorac Cardiovasc Surg 2001;122: Bach DS, Kon ND, Dumesnil JG, Sintek CF, Doty DB. Ten-year outcome after aortic valve replacement with the Freestyle stentless bioprosthesis. Ann Thorac Surg 2005;80: Jamieson WRE, Burr LH, Miyagishima RT, et al. Carpentier- Edwards supra-annular aortic porcine bioprosthesis: clinical performance over 20 years. J Thorac Cardiovasc Surg 2005; 130: O Brien MF, Gardner MAH, Gralick B, et al. CryoLife- O Brien stentless valve: 10-year results of 402 implants. Ann Thorac Surg 2005;79: Desai ND, Merin O, Cohen GD, et al. Long-term results of aortic valve replacement with the St. Jude Toronto stentless porcine valve. Ann Thorac Surg 2004;78: Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 2003;41: Kon ND, Westaby S, Amarasena N, Pillai R, Cordell AR. Comparison of implant techniques using the freestyle stentless porcine aortic valve. Ann Thorac Surg 1995;59: Bach DS, Cartier PA, Kon N, Johnson KG, Dumesnil JG, Doty DB. Impact of high transvalvular to subvalvular velocity ratio early after aortic valve replacement with Freestyle stentless aortic bioprosthesis. Sem Thorac Cardiovasc Surg 2001;13: Bach DS, Lemire MS, Eberhart D, Armstrong WF, Deeb GM. Impact of high transvalvular velocities early after implantation of Freestyle stentless aortic bioprosthesis. J Heart Valve Dis 2000;9: Matsue H, Sawa Y, Takahashi T, et al. Three-dimensional flow velocity quantification of Freestyle aortic stentless bioprosthesis by magnetic resonance imaging: surgical considerations. Sem Thorac Cardiovasc Surg 2001;13: Jin XY, Westaby S. In vivo hemodynamic characteristics of porcine stentless aortic valves. Semin Thorac Cardiovasc Surg 2001;13(4 Suppl 1): Kunihara T, Schmidt K, Glombitza P, Dzindzibadze V, Lausberg H, Schafers HJ. Root replacement using stentless valves in the small aortic root: a propensity score analysis. Ann Thorac Surg 2006;82: Mohammadi S, Baillot R, Voisine P, Mathieu P, Dagenais F. Structural deterioration of the Freestyle aortic valve: mode of presentation and mechanisms. J Thorac Cardiovasc Surg 2006;132: Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the veterans affairs randomized trial. J Am Coll Cardiol 2000;36: Schroll M, Schlettwein D, van Staveren W, et al. Health related quality of life and physical performance. SENECA J Nutr Health Aging 2002;6:15 9. DISCUSSION DR OCTAVIO E. PAJARO (Jacksonville, FL): Early on in this study, what was the basis to make the decision whether to use a subcoronary technique or the full-root replacement? DR J. ENNKER: Well, we learned that in the early days mortality for the full-root procedure was substantially higher, up to 10%. And if you have, for example, an 84-year-old lady on steroids for
9 Ann Thorac Surg ENNKER ET AL 2008;85: FULL-ROOT VERSUS SUBCORONARY IMPLANTATION 453 COPD (chronic obstructive pulmonary disease), she has a substantially enlarged risk for perioperative mortality when replacing the full root. And you may note that we did not use this again, stented valves, also in the aged population. So this was our concern. And the literature is up to 10%. And I know even other reports where they are worse. DR JOSEPH E. BAVARIA (Philadelphia, PA): That is a beautiful series. I just wanted to know whether you have the data on structural valve deterioration and AI (aortic insufficiency) formation and some of the other hemodynamic determinants for full-root replacement in patients less than age 60? Is the prosthesis, in your experience, deteriorating a littler faster in this age group? What is your opinion? DR J. ENNKER: This experience is too young. We have been doing so during the last 3 to 4 years, and I have to wait. We had no redo. We will give a presentation at the German meeting in 2 weeks. And together with Professor Lass from Bad Bevensen, we have 250 patients younger than 64. I will send you the presentation. DR MICHAEL BORGER (Leipzig, Germany): Excellent presentation. You are one of many groups now showing that the Freestyle has very good long-term results. You stated that you did not put in any stented valves last year. Do you think there is any benefit for a patient who has a relatively large aortic annulus, not so large that they require a total root replacement, but somebody who has a 32-mm aortic annulus and you can easily insert a 27 or a 29 stented valve with a shorter ischemic time? Is there any benefit for this type of patient to insert a stentless valve? DR J. ENNKER: Well, that is a matter of philosophy. And once we were convinced that this is a better valve, I stuck to this. But I do not argue if you implant a stented valve in a 25 or 27 root. This is all too possible, no doubt. DR MICHAEL E. JESSEN (Dallas, TX): You showed interesting data that the quality-of-life measures were better with the full root and that the gradients were lower. Do you have any information on LV (left ventricular) mass regression or heart failure class in these patients afterwards? Were they similar, or were they better with the full root? DR J. ENNKER: Well, the lesser gradient is a better result you can expect for regression of the left ventricular mass. However, there are reports in the literature that after 1 year there is no difference. But anyway, the patients definitely would benefit in the long run.
S ince the two large randomised trials of the 1970s
23 CARDIOVASCULAR MEDICINE Mid term outcome and quality of life after aortic valve replacement in elderly people: mechanical versus stentless biological valves I Florath, A Albert, U Rosendahl, T Alexander,
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationEight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis
Eight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis Neal D. Kon, MD,* Robert D. Riley, MD, Sandy M. Adair, RN, Dalane W. Kitzman, MD, and A. Robert
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationValve prosthesis-patient mismatch (PPM) was first defined
Impact of Valve Prosthesis-Patient Mismatch on Short-Term Mortality After Aortic Valve Replacement Claudia Blais, BSc; Jean G. Dumesnil, MD; Richard Baillot, MD; Serge Simard, MS; Daniel Doyle, MD; Philippe
More informationManagement of Difficult Aortic Root, Old and New solutions
Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationStentless aortic valves. Current aspects
Endorsed by proceedings in Intensive Care Cardiovascular Anesthesia EXPERT OPINION HSR Proceedings in Intensive Care and Cardiovascular Anesthesia 2012; 4(2): 77-82 Stentless aortic valves. Current aspects
More informationInfluence of patient gender on mortality after aortic valve replacement for aortic stenosis
Influence of patient gender on mortality after aortic valve replacement for aortic stenosis Jennifer Higgins, MD, W. R. Eric Jamieson, MD, Osama Benhameid, MD, Jian Ye, MD, Anson Cheung, MD, Peter Skarsgard,
More informationA 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationProsthetic valve dysfunction: stenosis or regurgitation
Prosthetic valve dysfunction: stenosis or regurgitation Jean G. Dumesnil MD, FRCP(C), FACC, FASE(Hon) Quebec Heart and Lung Institute, Québec, Québec No disclosures Possible Causes of High Gradients in
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More informationEffect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival
Effect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival Sukumaran K. Nair, FRCS (C Th), Gauraang Bhatnagar, MBBS, Oswaldo Valencia, MD, and Venkatachalam Chandrasekaran,
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationExperience with 500 Stentless Aortic Valve Replacements
Experience with 500 Stentless Aortic Valve Replacements Dimitrios C. Iliopoulos, MD Cardiac Surgeon Ass. Professor of Surgery University of Athens, School of Medicine I declare no conflict of interest
More informationHemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves
Hemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves Speaker's name: I have the following potential conflicts of interest to report: Proctorship for Medtronic Agenda Failure modes
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationQUANTIFICATION AND PREVENTION TECHNIQUES OF PROSTHESIS-PATIENT MISMATCH
QUANTIFICATION AND PREVENTION TECHNIQUES OF PROSTHESIS-PATIENT MISMATCH 1,2 Radu A. SASCĂU 3 Cristina OLARIU 1,2 Cristian STĂTESCU 1 Internal Medicine Department, Gr.T.Popa University of Medicine and Pharmacy,
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationIntensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)
European Heart Journal Supplements () 3 (Supplement Q), Q39 Q43 Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA
More informationAortic stenosis is the most common acquired heart valve. The Toronto Root Bioprosthesis: Midterm Results in 186 Patients
The Toronto Root Bioprosthesis: Midterm Results in 186 Patients Sven Lehmann, MD, Thomas Walther, MD, PhD, Sergey Leontyev, MD, Jörg Kempfert, MD, Jens Garbade, MD, Michael A. Borger, MD, PhD, and Friedrich
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationAlthough mitral valve replacement (MVR) is no longer the surgical
Surgery for Acquired Cardiovascular Disease Ruel et al Late incidence and predictors of persistent or recurrent heart failure in patients with mitral prosthetic valves Marc Ruel, MD, MPH a,b Fraser D.
More informationPPM: How to fit a big valve in a small heart
PPM: How to fit a big valve in a small heart Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC King Abdulaziz Cardiac Centre National Guard Health Affairs Riyadh, Saudi Arabia GHA meeting Muscat
More informationTissue vs Mechanical What s the Data??
Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/28521 holds various files of this Leiden University dissertation Author: Katsanos, Spyridon Title: Outcomes of transcatheter aortic valve implantation Issue
More informationLate incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves
Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves Marc Ruel, MD, MPH a,b Fraser D. Rubens, MD a Roy G. Masters, MD a Andrew L. Pipe, MD a
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationAortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years experience in 130 patients
Aortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years experience in 130 patients Augusto D Onofrio, MD, Stefano Auriemma, MD, Paolo Magagna, MD, Alessandro Favaro, MD,
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationBioprostheses are prone to continuous degeneration
Twenty-Year Experience With the St. Jude Medical Biocor Bioprosthesis in the Aortic Position Walter B. Eichinger, MD, Ina M. Hettich, MD, Daniel J. Ruzicka, MD, Klaus Holper, MD, Carolin Schricker, Sabine
More informationUse of Stentless Xenografts in the Aortic Position: Determinants of Early and Late Outcome
Use of Stentless Xenografts in the Aortic Position: Determinants of Early and Late Outcome A. Ruchan Akar, MD, Adam Szafranek, MD, Christos Alexiou, FRCS, Robert Janas, MD, Marek J. Jasinski, MD, Justiaan
More informationStentless aortic xenografts were introduced a decade
Survival After Stentless and Stented Xenograft Aortic Valve Replacement: A Concurrent, Controlled Trial Giovanni Battista Luciani, MD, Gianluca Casali, MD, Stefano Auriemma, MD, Francesco Santini, MD,
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationCopyright by ICR Publishers 2014
Comprehensive Hemodynamic Performance and Frequency of Patient-Prosthesis Mismatch of the St. Jude Medical Trifecta Bioprosthetic Aortic Valve Ajay Yadlapati 1, Jimmy Diep 3, Mary-Jo Barnes 2, Tristan
More informationCarpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years
Surgery for Acquired Cardiovascular Disease Carpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, Robert T. Miyagishima,
More informationMechanical Tricuspid Valve Replacement Is Not Superior in Patients Younger Than 65 Years Who Need Long-Term Anticoagulation
Mechanical Tricuspid Valve Replacement Is Not Superior in Patients Younger Than 65 Years Who Need Long-Term Anticoagulation Ho Young Hwang, MD, PhD, Kyung-Hwan Kim, MD, PhD, Ki-Bong Kim, MD, PhD, and Hyuk
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationProf. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM
The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationVery Long-Term Survival Implications of Heart Valve Replacement With Tissue Versus Mechanical Prostheses in Adults <60 Years of Age
Very Long-Term Survival Implications of Heart Valve Replacement With Versus Prostheses in Adults
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationCase. 15-year-old boy with bicuspid AV Severe AR with moderate AS. Ross vs. AVR (or AVP)
Case 15-year-old boy with bicuspid AV Severe AR with moderate AS Ross vs. AVR (or AVP) AMC case 14-year-old boy with bicuspid AV Severe AS with mild AR Body size Bwt: 55 kg, Ht: 154 cm, BSA: 1.53 m 2 Echocardiography
More informationMagdalena Erlebach 1, Michael Wottke 1, Marcus-André Deutsch 1, Markus Krane 1, Nicolo Piazza 2, Ruediger Lange 1, Sabine Bleiziffer 1
Original Article on TAVI Redo aortic valve surgery versus transcatheter valve-in-valve implantation for failing surgical bioprosthetic valves: consecutive patients in a single-center setting Magdalena
More informationIn , three studies described patients
Heart 2001;85:337 341 VALVE DISEASE Should patients with asymptomatic mild or moderate aortic stenosis undergoing coronary artery bypass surgery also have valve replacement for their aortic stenosis? Shahbudin
More informationDurability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado
More informationProsthesis-Patient Mismatch or Prosthetic Valve Stenosis?
EuroValves 2015, Nice Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis? Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE FESC Canada Research Chair in Valvular Heart Diseases Université LAVAL Disclosure
More informationClinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis
CLINICS 2012;67(1):55-60 DOI:10.6061/clinics/2012(01)09 CLINICAL SCIENCE Clinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis Luis M. Astudillo, I Orlando
More informationThe impact of prosthesis patient mismatch after aortic valve replacement varies according to age at operation
Editor s choice Scan to access more free content 1 Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, Maryland, USA 2 Division of Cardiac Surgery, University of Ottawa Heart Institute,
More informationSurgery for Acquired Cardiovascular Disease
Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement W. R. E. Jamieson, MD, O. von Lipinski, MD, R. T.
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationNineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up
Nineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up Dilip Sawant, FRCS, Arun K. Singh, MD, William C. Feng, MD, Arthur A. Bert, MD, and Fred Rotenberg, MD
More informationHemodynamics and Early Clinical Performance of the St. Jude Medical Regent Mechanical Aortic Valve
Hemodynamics and Early Clinical Performance of the St. Jude Medical Regent Mechanical Aortic Valve David S. Bach, MD, Marc P. Sakwa, MD, Martin Goldbach, MD, Michael R. Petracek, MD, Robert W. Emery, MD,
More informationMitral Gradients and Frequency of Recurrence of Mitral Regurgitation After Ring Annuloplasty for Ischemic Mitral Regurgitation
Mitral Gradients and Frequency of Recurrence of Mitral Regurgitation After Ring Annuloplasty for Ischemic Mitral Regurgitation Matthew L. Williams, MD, Mani A. Daneshmand, MD, James G. Jollis, MD, John
More informationTAVR: Echo Measurements Pre, Post And Intra Procedure
2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationEleven years experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with long-term relative survival rate
European Journal of Cardio-thoracic Surgery 22 (2002) 912 921 www.elsevier.com/locate/ejcts Eleven years experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationReoperations after primary aortic valve replacement
Third-Time Aortic Valve Replacement: Patient s and Operative Outcome Kasra Shaikhrezai, MD, MRCS, Giordano Tasca, MD, FETCS, Mohamed Amrani, PhD, FETCS, Gilles Dreyfus, MD, FETCS, and George Asimakopoulos,
More informationEarly and One-year Outcomes of Aortic Root Surgery in Marfan Syndrome Patients
Early and One-year Outcomes of Aortic Root Surgery in Marfan Syndrome Patients A Prospective, Multi-Center, Comparative Study Joseph S. Coselli, Irina V. Volguina, Scott A. LeMaire, Thoralf M. Sundt, Elizabeth
More informationChoice of Prosthetic Heart Valve in Adults
Journal of the American College of Cardiology Vol. 55, No. 22, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.085
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationInterventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504
Transcatheter valve-in-valve e implantation for aortic bioprosthetic valve dysfunction Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504 Your responsibility This
More informationAortic Valve Replacement or Heart Transplantation in Patients With Aortic Stenosis and Severe Left Ventricular Dysfunction
Aortic Valve Replacement or Heart Transplantation in Patients With Aortic Stenosis and Severe Left Ventricular Dysfunction L.S.C. Czer, S. Goland, H.J. Soukiasian, S. Gallagher, M.A. De Robertis, J. Mirocha,
More informationPatient/prosthesis mismatch: how to evaluate and when to act?
Patient/prosthesis mismatch: how to evaluate and when to act? Svend Aakhus, MD, PhD Oslo University Hospital, Norway Disclosures: No conflict of interest Types of aortic valve prostheses (AVR) Mechanical
More informationRESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES
e-issn:2322-0139 RESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES Comparative Evaluation of Safety Outcomes of Different Prosthetic Valves in Indian Subjects. Kama Raval 1 *, Reena
More informationMulticentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system
Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist
More informationSurgery for Valvular Heart Disease. Reoperation of Left Heart Valve Bioprostheses According to Age at Implantation
Surgery for Valvular Heart Disease Reoperation of Left Heart Valve Bioprostheses According to Age at Implantation Vincent Chan, MD, MPH; Tarek Malas, MD; Harry Lapierre, MD; Munir Boodhwani, MMSc, MD;
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationThe increase in the lifespan of the western population
Outcome After Aortic Valve Replacement in Octogenarians Bruno Chiappini, MD, Nicola Camurri, MD, Antonio Loforte, MD, Luca Di Marco, MD, Roberto Di Bartolomeo, MD, and Giuseppe Marinelli, MD Department
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationValvular Heart Disease
Valvular Heart Disease B K Singh, MD, FACC Disclosures: None 1 CARDIAC CYCLE S2 S2=A2P2 S1=M1T1 S4 S1 S3 2 JVP Carotid S1 Slitting of S2 S3 S4 Ejection click Opening snap Dynamic Auscultation What is the
More informationRegression of Hypertrophy After Carpentier-Edwards Pericardial Aortic Valve Replacement
Regression of Hypertrophy After Carpentier-Edwards Pericardial Aortic Valve Replacement Steven S. Khan, MD, Robert J. Siegel, MD, Michele A. DeRobertis, RN, Carlos E. Blanche, MD, Robert M. Kass, MD, Wen
More informationIschemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications
Surgery for Acquired Cardiovascular Disease Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications Eugene A. Grossi, MD Judith D. Goldberg, ScD Angelo
More informationSurgery for Acquired Cardiovascular Disease ACD
Surgery for Acquired Cardiovascular Disease Clinical outcomes after separate and composite replacement of the aortic valve and ascending aorta Thanos Sioris, MD Tirone E. David, MD Joan Ivanov, PhD Susan
More informationRe-do aortic valve replacement after previous homograft aortic root replacement
Re-do aortic valve replacement after previous homograft aortic root replacement Jullien Gaer, Toufan Bahrami, Fabio de Robertis, Ahmed Abdulsalam, John Pepper, NHS Foundation Trust, UK Professor Sir Magdi
More informationEmergency Intraoperative Echocardiography
Emergency Intraoperative Echocardiography Justiaan Swanevelder Department of Anaesthesia, Glenfield Hospital University Hospitals of Leicester NHS Trust, UK Carl Gustav Jung (1875-1961) Your vision will
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationStentless aortic valve replacement in the young patient: long-term results
Christ et al. Journal of Cardiothoracic Surgery 2013, 8:68 RESEARCH ARTICLE Open Access Stentless aortic valve replacement in the young patient: long-term results Torsten Christ *, Herko Grubitzsch, Benjamin
More informationReconstruction of the intervalvular fibrous body during aortic and
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,
More informationAnn Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article
Ann Thorac Cardiovasc Surg 2015; 21: 53 58 Online April 18, 2014 doi: 10.5761/atcs.oa.13-00364 Original Article The Impact of Preoperative and Postoperative Pulmonary Hypertension on Long-Term Surgical
More informationJournal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, 9, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.04.062 Relation
More informationFavorable Results in Patients with Small Size CarboMedics Heart Valves in the Aortic Position
Favorable Results in Patients with Small Size CarboMedics Heart Valves in the Aortic Position Kazuhito Imanaka, MD, Shinichi Takamoto, MD, and Akira Furuse, MD 2 Hemodynamic performance of the CarboMedics
More informationFocused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig.
ACC/AH HA 2006 Guidel nic severe AI (Fig. 4). ned by age, ay also be helpful nd echo. For AI, ollow up may be or MRI rather than mension; SD, end lines for Manag gement of Patie Upd ents With Valvul date
More informationTranscatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital,
Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital, Oslo, Norway Aortic regurgitation Prevalence in Framingham
More information